Subscribe to RSS
DOI: 10.1055/a-1532-2384
Cytotoxicity of Poupartone B, an Alkyl Cyclohexenone Derivative from Poupartia borbonica, against Human Cancer Cell Lines[ # ]
Abstract
Poupartia borbonica is an endemic tree from the Mascarene Islands that belongs to the Anacardiaceae family. The leaves of this plant were phytochemically studied previously, and isolated alkyl cyclohexenone derivatives, poupartones A – C, demonstrated antiplasmodial and antimalarial activities. In addition to their high potency against the Plasmodium sp., high toxicity on human cells was also displayed. The present study aims to investigate in more detail the cytotoxicity and pharmacological interest of poupartone B, one of the most abundant derivatives in the leaves of P. borbonica. For that purpose, real-time live-cell imaging of different human cancer cell lines and normal fibroblasts, treated or not treated with poupartone B, was performed. A potent inhibition of cell proliferation associated with the induction of cell death was observed. A detailed morphological analysis of different adherent cell lines exposed to high concentrations of poupartone B (1 – 2 µg/mL) demonstrated that this compound induced an array of cellular alterations, including a rapid retraction of cellular protrusions associated with cell rounding, massive cytoplasmic vacuolization, loss of plasma membrane integrity, and plasma membrane bubbling, ultimately leading to paraptosis-like cell death. The structure-activity relation of this class of compounds, their selective toxicity, and pharmacological potential are discussed.
Key words
Anacardiaceae - Poupartia borbonica - poupartone B - cancer - cytotoxicity - live-cell imaging# Dedicated to Professor Arnold Vlietinck on the occasion of his 80th birthday.
* MF and EM are co-senior authors of this work.
Supporting Information
- Supporting Information
MDA-MB-231 cells were treated with increasing concentrations of poupartone B (0.5 – 2 µg/mL) or vehicle only. Phase-contrast time-lapse images of the different culture conditions after 0, 6, 12, 24, 36, and 48 h of treatment are illustrated in Fig. 1S (Supporting Information). A2058 cells were treated with increasing concentrations of poupartone B (0.5 – 2 µg/mL) or vehicle only. Phase-contrast time-lapse images of the different culture conditions after 0, 6, 12, 24, 36, and 48 h of treatment are illustrated in Fig. 2S (Supporting Information). A375 cells were treated with increasing concentrations of poupartone B (0.5 – 2 µg/mL) or vehicle only. Phase-contrast time-lapse images of the different culture conditions after 0, 6, 12, 24, 36, and 48 h of treatment are illustrated in Fig. 3S (Supporting Information). Fibroblasts were treated with increasing concentrations of poupartone B (0.5 – 2 µg/mL) or vehicle only. Phase-contrast time-lapse images of the different culture conditions after 0, 6, 12, 24, 36, and 48 h of treatment are illustrated in Fig. 4S (Supporting Information).
MDA-MB-231, A2058, A375, normal fibroblasts, HL-60, and OCI-LY19 cells were treated with increasing concentrations (0 – 2 µg/mL) of poupartone B, and live-cell imaging was used to measure the relative cell confluency. The areas under the relative cell confluency versus time curves (AUC) are plotted for each concentration tested. Dose-response curves (gray curves) were fitted using the inhibitory concentration versus response–variable slope (4 parameters) function of Graphpad Prism. A representative experiment is illustrated in Fig. 5S (Supporting Information).
MDA-MB-231 cells were exposed to poupartone B (1 µg/mL), and time-lapse imaging by holo-tomographic microscopy was performed for 13 h; the video is available as Supporting Information.
Publication History
Received: 15 January 2021
Accepted after revision: 14 June 2021
Article published online:
16 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Ledoux A, St-Gelais A, Cieckiewicz E, Jansen O, Bordignon A, Illien B, Di Giovanni N, Marvilliers A, Hoareau F, Pendeville H, Quetin-Leclercq J, Frédérich M. Antimalarial activities of alkyl cyclohexenone derivatives isolated from the leaves of Poupartia borbonica . J Nat Prod 2017; 80: 1750-1757
- 2 Otto A, Porzel A, Schmidt J, Brandt W, Wessjohann L, Arnold N. Structure and absolute configuration of pseudohygrophorones A 12 and B 12, alkyl cyclohexenone derivatives from Hygrophorus abieticola (Basidiomycetes). J Nat Prod 2016; 79: 74-80
- 3 Roumy V, Fabre N, Portet B, Bourdy G, Acebey L, Vigor C, Valentin A, Moulis C. Four anti-protozoal and anti-bacterial compounds from Tapirira guianensis . Phytochemistry 2009; 70: 305-311
- 4 David JM, Chavez JP, Chai HB, Pezzuto JM, Cordell GA. New cytotoxic compounds from Tapirira guianensis . J Nat Prod 1998; 61: 287-289
- 5 Correia SDJ, David JM, David JP, Chai HB, Pezzuto JM, Cordell GA. Alkyl phenols and derivatives from Tapirira obtusa . Phytochemistry 2001; 56: 781-784
- 6 Okoth DA, Akala HM, Johnson JD, Koorbanally NA. Alkyl phenols, alkenyl cyclohexenones and other phytochemical constituents from Lannea rivae (chiov) Sacleux (Anacardiaceae) and their bioactivity. Med Chem Res 2016; 25: 690-703
- 7 Yaouba S, Koch A, Guantai EM, Derese S, Irungu B, Heydenreich M, Yenesew A. Alkenyl cyclohexanone derivatives from Lannea rivae and Lannea schweinfurthii . Phytochem Lett 2017; 23: 141-148
- 8 Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods 2016; 13: 521-527
- 9 Reuven N, Adler J, Meltser V, Shaul Y. The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ 2013; 20: 1330-1340
- 10 Schonn I, Hennesen J, Dartsch DC. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 2010; 15: 162-172
- 11 Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ. A landscape of pharmacogenomic interactions in cancer. Cell 2016; 166: 740-754
- 12 Sperandio S, Poksay KS, Schilling B, Crippen D, Gibson BW, Bredesen DE. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 2010; 111: 1401-1412
- 13 Ranjan A, Iwakuma T. Non-canonical cell death induced by p53. Int J Mol Sci 2016; 17: 2068
- 14 Lee D, Kim IY, Saha S, Choi KS. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol Ther 2016; 162: 120-133
- 15 Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 2015; 35: S78-S103
- 16 Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 2019; 575: 299-309
- 17 Yuan R, Hou Y, Sun W, Yu J, Liu X, Niu Y, Lu JJ, Chen X. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci 2017; 1401: 19-27